Survinin expression in patients with breast cancer during chemotherapy

Tumor Biology

Volumn 36, Issue 5, 2015, Pages 3441-3445

  Marsicano, S R ^a   Kuniyoshi, R K ^a   Gehrke, F S ^a   Alves, B C A ^a   Azzalis, L A ^b   Fonseca, F L A ^a,b  

^a Oncology and Hematology Department ABC Medical School   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Metastatic disease; Neoplasm; Prognostic marker; Survinin

Indexed keywords

CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DIGOXIN; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; SURVIVIN; ZOLEDRONIC ACID; BIRC5 PROTEIN, HUMAN; CARCINOEMBRYONIC ANTIGEN; INHIBITOR OF APOPTOSIS PROTEIN; MUCIN 1;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENE EXPRESSION; HUMAN; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; BREAST NEOPLASMS; GENETICS; METABOLISM; MIDDLE AGED; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LOGISTIC MODELS; MIDDLE AGED; MUCIN-1;

EID: 84929953242     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2979-5     Document Type: Article

References (19)

1. Silva APR, Noronha CP, Silva JLO, Ferreira JMO, Oliveira JFP, Santos MO. Estimativa 2012 Incidência de Câncer no Brasil. 2012. http://portal.saude.sp.gov.br/resources/ses/perfil/gestor/homepage/estimativas-de-incidencia-de-cancer-2012/estimativas_incidencia_cancer_2012.pdf. Accessed 03 Oct 2014.
2. Guimarães BM, Silva C, Noronha CP, Silva GS, Oliveira JFP, Pereira KA. Estimativa 2014 Incidência de Câncer no Brasil. 2014. http://www.inca.gov.br/estimativa/2014/estimativa-24012014.pdf. Accessed 27 Jan 2014.
3. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: isolation and approaches to characterization. J Cell Biol. 2011;192:373–82.
4. Pantel K, Panabie CA. Circulating tumor cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16:398–406.
5. Yoshihara RN, Teixeira BM, Adami F, Kuniyoshi RK, Alves BCA, Gehrke FS, et al. Circulating tumor cell detection during chemotherapy in patients with breast cancer is not associated with plasma homocysteine levels. Tumor Biol. 2013;34:2937–41.
6. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–21.
7. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8:61–70.
8. Jha K, Shukla M, Pandey M. Survivin expression and targeting in breast cancer. Surg Oncol. 2012;21:125–31.
9. Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Springer Curr Oncol Rep. 2012;14:120–8.
10. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 2004;114:1117–27.
11. Span PN, Heijnen VCGT, Heuvel JJTM, Kok JB, Foekens JA, Sweep FCGJ. Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer? Clin Chem. 2006;52:1693–700.
12. Kelly AE, Ghenoiu C, Xue JZ, Zierhut C, Kimura H, et al. Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B. Science. 2010 Science 8 October 2010: Vol. 330 no. 6001 pp. 235–9.
13. Yamagishi Y, Honda T, Tanno Y, Watanabe Y. Two histone marks establish themselves the inner centromere and chromosome bi-orientation. Science. 2010;330:235–9.
14. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC. IAP regulation of metastasis. Cancer Cell. 2010;17:53–64.
15. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerberl RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. PNAS. 2002;99:4349–54.
16. Caldas H, Fangusaro JR, Boue DR, Holloway MP, Altura RA. Dissecting the role of DeltaEx3 endothelial survivin in angiogenesis. Blood. 2007;109:1479–89.
17. Johnen G, Gawrych K, Bontrup H, Pesch B, Taeger D, Banek S, et al. Performance of survivin mRNA as a biomarker for bladder cancer in the prospective study UroScreen. Plos One. 2012. doi:10.1371/journal.pone.0035363.
18. Marsicano SR, Pinto JLF, Delgado PO, Coelho PG, Fonseca FLA. Systemic chemotherapy-induced microsatellite instability in the mononuclear cell fraction of women with breast cancer can be reproduced in vitro and abrogated by amifostine. J Pharm Pharmacol. 2010;62:931–4.
19. Yamashita EK, Teixeira BM, Yoshihara RN, Kuniyoshi RK, Alves BCA, Gehrke FS, et al. Systemic chemotherapy interferes in homocysteine metabolism in breast cancer patients. J Clin Lab Anal. 2014;28:157–62.